Metizolam: Designer Thienodiazepine, Metabolism, Amnesia & 2026 Forensic Evidence
What the evidence actually shows
Evidence Very LowDirect answer
Evidence review of metizolam, a designer thienodiazepine related to etizolam, covering human metabolism, urine detection, intoxication and drug-facilitated assault evidence, dependence, and major data gaps. Metizolam is a designer thienodiazepine structurally related to etizolam. Published human work has characterized urinary detection and metabolism, but controlled safety data remain sparse. A 2026 forensic case documented metizolam in a drug-facilitated sexual assault investigation, highlighting amnesia and detection challenges.
Research brief
Questions this page answers
- What is metizolam?
- Is metizolam related to etizolam?
- How is metizolam detected?
- Can metizolam cause amnesia?
Signal
Scientific takeaways
- Metizolam is a designer thienodiazepine structurally related to etizolam.
- Published human work has characterized urinary detection and metabolism, but controlled safety data remain sparse.
- A 2026 forensic case documented metizolam in a drug-facilitated sexual assault investigation, highlighting amnesia and detection challenges.
Metizolam: Designer Thienodiazepine, Metabolism, Amnesia & 2026 Forensic Evidence
Quick answer
Metizolam is a designer thienodiazepine structurally related to etizolam.
It has appeared in online research-chemical markets and clinical toxicology, but human data remain limited.
Published evidence includes:
- a human metabolism/detection study;
- intoxication surveillance;
- a 2026 drug-facilitated sexual assault case.
Relationship to etizolam
Metizolam differs chemically from etizolam but retains benzodiazepine-like GABA-A receptor effects.
The similarity of names can encourage simplistic equivalence claims.
The available evidence does not support assuming identical potency, half-life, or risk.
Human metabolism study
A 2017 study administered metizolam in a controlled analytical experiment and tracked urine over several days.
Researchers identified unchanged drug and multiple metabolites.
The study was primarily designed to improve forensic detection, not to establish therapeutic or recreational safety.
2026 drug-facilitated assault evidence
A 2026 forensic report described metizolam identified in the urine of a teenager evaluated after suspected drug-facilitated sexual assault with amnesia.
The report emphasized a broader analytical problem: newer benzodiazepines can be present at low concentrations and may be absent from routine screening panels.
Advanced LC-MS/MS or LC-HRMS methods may be required.
Effects and risks
Expected benzodiazepine-type effects include:
- sedation;
- impaired coordination;
- reduced anxiety;
- amnesia;
- disinhibition;
- impaired judgment.
Alcohol and other depressants can amplify those effects.
Dependence and withdrawal
Repeated exposure can produce benzodiazepine-type dependence.
Abrupt withdrawal after dependence can be medically dangerous and may include seizures.
Reddit signal
Metizolam appears less frequently than bromazolam or clonazolam but remains part of the long tail of RC benzos discussed in online communities.
The scientific literature is too thin to support precise user-generated potency rankings.
Why similarity to etizolam is not a conversion rule
Metizolam is often discussed through comparison with etizolam because the structures and naming are related. That comparison is useful for orientation, but it should not be turned into a numerical potency or duration conversion. Small structural changes can alter receptor activity, metabolism, and active-metabolite profiles, while unregulated products add uncertainty about concentration and identity.
Dependence and withdrawal
As a benzodiazepine-type sedative, metizolam carries a plausible risk of tolerance and physical dependence with repeated exposure. Severe withdrawal from benzodiazepine-type drugs can include marked anxiety, insomnia, tremor, confusion, perceptual disturbance, and seizures. Direct metizolam withdrawal data are too limited to support a precise timeline or self-taper formula.
Interactions
Alcohol, opioids, sedative-hypnotics, gabapentinoids, and other benzodiazepines can add to sedation and respiratory danger. A person may also be exposed unknowingly if a counterfeit or mixed product contains more than one depressant. That makes product testing and conservative interpretation more important than subjective similarity to a familiar drug.
Laboratory detection
Routine benzodiazepine screening does not guarantee recognition of every designer analogue. Confirmatory LC-MS/MS or high-resolution mass spectrometry with updated standards is better suited to distinguishing compounds and metabolites. A negative screening test therefore should not be treated as definitive proof of absence.
What the evidence can support
Analytical identification and real-world detection can establish that metizolam is present in the drug market. They do not establish a pharmaceutical-grade safety margin. Until controlled human data are substantially stronger, the site should avoid equivalence charts and keep the emphasis on class risk, uncertain product composition, and careful toxicology interpretation.
Bottom line
Metizolam is analytically and clinically real, but still poorly characterized.
Recent forensic evidence makes its amnestic potential and detection challenges especially relevant.
Related evidence
Source ledger
References
3 sources
- 01Detection of the designer benzodiazepine metizolam in urine and preliminary data on its metabolism Kintz P, Richeval C, Jamey C, et al. · 2017PMID 27671107DOI 10.1002/dta.2099 PubMed →
- 02First case of drug-facilitated sexual assault involving metizolam Bellouard M, et al. · 2026PMID 42373881DOI 10.1007/s00414-026-03897-9 PubMed →
- 03Occurrence and time course of NPS benzodiazepines in Sweden - results from intoxication cases in the STRIDA project Bäckberg M, et al. · 2019PMID 30348014 PubMed →